{"id":"fipv-0-1ml-im","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site soreness, redness, or swelling"},{"rate":null,"effect":"Low-grade fever"},{"rate":null,"effect":"Irritability or fussiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"fIPV contains chemically inactivated (killed) poliovirus particles that trigger humoral and cellular immune responses without causing disease. The vaccine elicits production of neutralizing antibodies against poliovirus types 1, 2, and 3, providing protection against infection and transmission. The intramuscular route (0.1 mL dose) delivers the antigen for systemic immune priming.","oneSentence":"fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:31.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (polio) caused by poliovirus types 1, 2, and 3"}]},"trialDetails":[{"nctId":"NCT04063150","phase":"PHASE4","title":"Immunogenicity of Intramuscular and Intradermal IPV","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-06","conditions":"Poliomyelitis","enrollment":958}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"fIPV (0.1mL) IM","genericName":"fIPV (0.1mL) IM","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"fIPV (0.1mL) IM is a vaccine intervention being studied for its immunogenicity in routine immunization. It is specifically being investigated for its effectiveness in preventing Poliomyelitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}